Jae-Hyuck Shim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jae-Hyuck Shim has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Hwanhee Oh
Department of Pathology and Laboratory Medicine Weill Cornell Medicine, New York, NY 10065
3 shared publications- Kwang Hwan Park
Department of Orthopaedic Surgery, Yonsei University College of Medicine, Seoul, South Korea
3 shared publications Matthew B. Greenblatt
Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115 Department of Medicine and Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10065
3 shared publicationsBo Zhai
Department of Cell Biology, Harvard Medical School, Boston, MA 02115
2 shared publicationsDong Yeon Shin
Department of Pathology and Laboratory Medicine Weill Cornell Medicine, New York, NY 10065
2 shared publicationsDorothy Hu
Endocrine Unit, Massachusetts General Hospital, Boston, MA 02114
2 shared publications
Latest Publications
- 16 February 2016
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 113 (9) , E1226-E1235
MEKK2 mediates an alternative β-catenin pathway that promotes bone formation
Proper tuning of β-catenin activity in osteoblasts is required for bone homeostasis, because both increased and decreased β-catenin activity have pathologic consequences. In the classical pathway for β-catenin activation, stimulation with WNT ligands suppresses constitutive phosphorylation of β-catenin by glycogen synthase kinase 3β, preventing β-catenin ubiquitination and proteasomal degradation. Here, we have found that mitogen-activated protein kinase kinase kinase 2 (MAP3K2 or MEKK2) mediates an alternative pathway for β-catenin activation in osteoblasts that is distinct from the canonical WNT pathway. FGF2 activates MEKK2 to phosphorylate β-catenin at serine 675, promoting recruitment of the deubiquitinating enzyme, ubiquitin-specific peptidase 15 (USP15). USP15 in turn prevents the basal turnover of β-catenin by inhibiting its ubiquitin-dependent proteasomal degradation, thereby enhancing WNT signaling. Analysis of MEKK2-deficient mice and genetic interaction studies between Mekk2- and β-catenin–null alleles confirm that this pathway is an important physiologic regulator of bone mass in vivo. Thus, an FGF2/MEKK2 pathway mediates an alternative nonclassical pathway for β-catenin activation, and this pathway is a key regulator of bone formation by osteoblasts. Significance Here, we report a previously unidentified alternative pathway mediated by mitogen-activated protein kinase kinase kinase 2 (MEKK2) for the activation of β-catenin in osteoblasts that is distinct from the classical glycogen synthase kinase 3β (GSK3β)-mediated degradation pathway. The GSK3β pathway regulates β-catenin stability via β-catenin ubiquitination, and its inhibition prevents β-catenin degradation. The MEKK2 pathway instead rescues ubiquitinated β-catenin from degradation via deubiquitination. This pathway plays a critical role in controlling bone mass in vivo, and targeting this pathway may offer an attractive approach for the therapeutic regulation of β-catenin activity.
- 16 February 2016
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 113 (9) , E1226-E1235
MEKK2 mediates an alternative β-catenin pathway that promotes bone formation
Proper tuning of β-catenin activity in osteoblasts is required for bone homeostasis, because both increased and decreased β-catenin activity have pathologic consequences. In the classical pathway for β-catenin activation, stimulation with WNT ligands suppresses constitutive phosphorylation of β-catenin by glycogen synthase kinase 3β, preventing β-catenin ubiquitination and proteasomal degradation. Here, we have found that mitogen-activated protein kinase kinase kinase 2 (MAP3K2 or MEKK2) mediates an alternative pathway for β-catenin activation in osteoblasts that is distinct from the canonical WNT pathway. FGF2 activates MEKK2 to phosphorylate β-catenin at serine 675, promoting recruitment of the deubiquitinating enzyme, ubiquitin-specific peptidase 15 (USP15). USP15 in turn prevents the basal turnover of β-catenin by inhibiting its ubiquitin-dependent proteasomal degradation, thereby enhancing WNT signaling. Analysis of MEKK2-deficient mice and genetic interaction studies between Mekk2- and β-catenin–null alleles confirm that this pathway is an important physiologic regulator of bone mass in vivo. Thus, an FGF2/MEKK2 pathway mediates an alternative nonclassical pathway for β-catenin activation, and this pathway is a key regulator of bone formation by osteoblasts. Significance Here, we report a previously unidentified alternative pathway mediated by mitogen-activated protein kinase kinase kinase 2 (MEKK2) for the activation of β-catenin in osteoblasts that is distinct from the classical glycogen synthase kinase 3β (GSK3β)-mediated degradation pathway. The GSK3β pathway regulates β-catenin stability via β-catenin ubiquitination, and its inhibition prevents β-catenin degradation. The MEKK2 pathway instead rescues ubiquitinated β-catenin from degradation via deubiquitination. This pathway plays a critical role in controlling bone mass in vivo, and targeting this pathway may offer an attractive approach for the therapeutic regulation of β-catenin activity.
- 9 December 2015
- Published by Springer Nature in Osteoporosis International
- Vol. 27 (4) , 1559-1568
Polycythemia is associated with bone loss and reduced osteoblast activity in mice
Summary Increased fragility has been described in humans with polycythemia vera (PV). Herein, we describe an osteoporotic phenotype associated with decreased osteoblast activity in a mouse model of PV and another mouse of polycythemia and elevated circulating erythropoietin (EPO). Our results are important for patients with PV or those treated with recombinant EPO (rEPO). Introduction PV and other myeloproliferative syndromes have been recently associated with an increased risk for fractures. However, the presence of osteoporosis in these patients has not been well documented. EPO, a hormone primarily known to stimulate erythropoiesis, has been shown recently to regulate bone homeostasis in mice. The aim of this study was to examine the bone phenotype of a mouse model of PV and compare it to that of animals with polycythemia caused by elevated circulating EPO. Methods Bone mass and remodeling were evaluated by micro-computed tomography and histomorphometry. The JAK2V617F knock-in mouse, a model of human PV, manifests polycythemia and low circulating EPO levels. Results from this mouse were compared to wild type (wt) controls and the tg6 transgenic mouse that shows polycythemia caused by increased constitutive expression of EPO. Results Compared to wt, both JAK2V617F and tg6 mice had a decrease in trabecular bone mass. Tg6 mice showed an additional modest decrease in cortical thickness and cortical bone volume per tissue volume (P < 0.01) suggesting a more severe bone phenotype than JAK2V617F. Decreased osteoblast numbers and bone formation along with normal osteoclast numbers and activity were found in both mice. Conclusions This study indicates that PV is associated with low bone mass and decreased osteoblast activity in mice. Our results support future studies of osteoporosis in affected humans. Polycythemia caused by chronically elevated circulating EPO also results in bone loss, and implications on patients treated with rEPO should be evaluated.
- 9 December 2015
- Published by Springer Nature in Osteoporosis International
- Vol. 27 (4) , 1559-1568
Polycythemia is associated with bone loss and reduced osteoblast activity in mice
Summary Increased fragility has been described in humans with polycythemia vera (PV). Herein, we describe an osteoporotic phenotype associated with decreased osteoblast activity in a mouse model of PV and another mouse of polycythemia and elevated circulating erythropoietin (EPO). Our results are important for patients with PV or those treated with recombinant EPO (rEPO). Introduction PV and other myeloproliferative syndromes have been recently associated with an increased risk for fractures. However, the presence of osteoporosis in these patients has not been well documented. EPO, a hormone primarily known to stimulate erythropoiesis, has been shown recently to regulate bone homeostasis in mice. The aim of this study was to examine the bone phenotype of a mouse model of PV and compare it to that of animals with polycythemia caused by elevated circulating EPO. Methods Bone mass and remodeling were evaluated by micro-computed tomography and histomorphometry. The JAK2V617F knock-in mouse, a model of human PV, manifests polycythemia and low circulating EPO levels. Results from this mouse were compared to wild type (wt) controls and the tg6 transgenic mouse that shows polycythemia caused by increased constitutive expression of EPO. Results Compared to wt, both JAK2V617F and tg6 mice had a decrease in trabecular bone mass. Tg6 mice showed an additional modest decrease in cortical thickness and cortical bone volume per tissue volume (P < 0.01) suggesting a more severe bone phenotype than JAK2V617F. Decreased osteoblast numbers and bone formation along with normal osteoclast numbers and activity were found in both mice. Conclusions This study indicates that PV is associated with low bone mass and decreased osteoblast activity in mice. Our results support future studies of osteoporosis in affected humans. Polycythemia caused by chronically elevated circulating EPO also results in bone loss, and implications on patients treated with rEPO should be evaluated.
- Open Access
- 20 July 2015
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 212 (8) , 1283-1301
CHMP5 controls bone turnover rates by dampening NF-κB activity in osteoclasts
Physiological bone remodeling requires that bone formation by osteoblasts be tightly coupled to bone resorption by osteoclasts. However, relatively little is understood about how this coupling is regulated. Here, we demonstrate that modulation of NF-κB signaling in osteoclasts via a novel activity of charged multivesicular body protein 5 (CHMP5) is a key determinant of systemic rates of bone turnover. A conditional deletion of CHMP5 in osteoclasts leads to increased bone resorption by osteoclasts coupled with exuberant bone formation by osteoblasts, resembling an early onset, polyostotic form of human Paget’s disease of bone (PDB). These phenotypes are reversed by haploinsufficiency for Rank, as well as by antiresorptive treatments, including alendronate, zolendronate, and OPG-Fc. Accordingly, CHMP5-deficient osteoclasts display increased RANKL-induced NF-κB activation and osteoclast differentiation. Biochemical analysis demonstrated that CHMP5 cooperates with the PDB genetic risk factor valosin-containing protein (VCP/p97) to stabilize the inhibitor of NF-κBα (IκBα), down-regulating ubiquitination of IκBα via the deubiquitinating enzyme USP15. Thus, CHMP5 tunes NF-κB signaling downstream of RANK in osteoclasts to dampen osteoclast differentiation, osteoblast coupling and bone turnover rates, and disruption of CHMP5 activity results in a PDB-like skeletal disorder.
- 20 July 2015
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 212 (8) , 1283-1301
Open AccessCHMP5 controls bone turnover rates by dampening NF-κB activity in osteoclasts
Physiological bone remodeling requires that bone formation by osteoblasts be tightly coupled to bone resorption by osteoclasts. However, relatively little is understood about how this coupling is regulated. Here, we demonstrate that modulation of NF-κB signaling in osteoclasts via a novel activity of charged multivesicular body protein 5 (CHMP5) is a key determinant of systemic rates of bone turnover. A conditional deletion of CHMP5 in osteoclasts leads to increased bone resorption by osteoclasts coupled with exuberant bone formation by osteoblasts, resembling an early onset, polyostotic form of human Paget’s disease of bone (PDB). These phenotypes are reversed by haploinsufficiency for Rank, as well as by antiresorptive treatments, including alendronate, zolendronate, and OPG-Fc. Accordingly, CHMP5-deficient osteoclasts display increased RANKL-induced NF-κB activation and osteoclast differentiation. Biochemical analysis demonstrated that CHMP5 cooperates with the PDB genetic risk factor valosin-containing protein (VCP/p97) to stabilize the inhibitor of NF-κBα (IκBα), down-regulating ubiquitination of IκBα via the deubiquitinating enzyme USP15. Thus, CHMP5 tunes NF-κB signaling downstream of RANK in osteoclasts to dampen osteoclast differentiation, osteoblast coupling and bone turnover rates, and disruption of CHMP5 activity results in a PDB-like skeletal disorder.
- Open Access
- 1 January 2015
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 290 (1) , 284-295
p38α MAPK Is Required for Tooth Morphogenesis and Enamel Secretion
- 1 January 2015
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 290 (1) , 284-295
Open Accessp38α MAPK Is Required for Tooth Morphogenesis and Enamel Secretion
- Open Access
- 2 October 2013
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 11 (1) , 74
Zinc inhibits osteoclast differentiation by suppression of Ca2+-Calcineurin-NFATc1 signaling pathway
Background: Zinc, an essential trace element, inhibits osteoclast differentiation in vitro and in vivo. The molecular mechanism for the inhibitory effect of zinc, however, is poorly understood. The purpose of this study was to investigate the effect of zinc and determine its molecular mechanism on receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis in mouse bone marrow-derived monocyte cells (BMMs) and RAW264.7 cells.Results: In BMMs, zinc treatment during osteoclast differentiation decreased RANKL-induced osteoclast formation in a dose-dependent manner. We show that zinc suppressed the mRNA levels of nuclear factor of activated T-cells, cytoplasmic 1 (Nfatc1). Zinc also accumulated phospho-Nfatc1 (p-Nfatc1) in the cytosol in a dose-dependent manner and inhibited the translocation of Nfatc1 to the nucleus in RAW264.7 cells. Zinc suppressed the activities of Nfatc1 in the nucleus without changing the activities of NF-κB in RAW264.7 cells. In contrast, calcineurin activity decreased in response to zinc but its protein level was unchanged. RANKL-induced Ca2+oscillations were inhibited by zinc treatment, but phospho-phospholipase Cγ1 (p-PLCγ1), the upstream signaling molecule of Ca2+oscillations, was unaffected. Moreover, a constitutively active form of Nfatc1 obviously rescued suppression of osteoclastogenesis by zinc.Conclusions: Taken together, these results demonstrate for the first time that the inhibitory effect of zinc during osteoclastogesis is caused by suppressing the Ca2+-Calcineurin-NFATc1 signaling pathway. Thus, zinc may be a useful therapeutic candidate for the prevention of bone loss caused by NFATc1 activation in osteoclasts.
- 2 October 2013
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 11 (1) , 74
Open AccessZinc inhibits osteoclast differentiation by suppression of Ca2+-Calcineurin-NFATc1 signaling pathway
Background: Zinc, an essential trace element, inhibits osteoclast differentiation in vitro and in vivo. The molecular mechanism for the inhibitory effect of zinc, however, is poorly understood. The purpose of this study was to investigate the effect of zinc and determine its molecular mechanism on receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis in mouse bone marrow-derived monocyte cells (BMMs) and RAW264.7 cells.Results: In BMMs, zinc treatment during osteoclast differentiation decreased RANKL-induced osteoclast formation in a dose-dependent manner. We show that zinc suppressed the mRNA levels of nuclear factor of activated T-cells, cytoplasmic 1 (Nfatc1). Zinc also accumulated phospho-Nfatc1 (p-Nfatc1) in the cytosol in a dose-dependent manner and inhibited the translocation of Nfatc1 to the nucleus in RAW264.7 cells. Zinc suppressed the activities of Nfatc1 in the nucleus without changing the activities of NF-κB in RAW264.7 cells. In contrast, calcineurin activity decreased in response to zinc but its protein level was unchanged. RANKL-induced Ca2+oscillations were inhibited by zinc treatment, but phospho-phospholipase Cγ1 (p-PLCγ1), the upstream signaling molecule of Ca2+oscillations, was unaffected. Moreover, a constitutively active form of Nfatc1 obviously rescued suppression of osteoclastogenesis by zinc.Conclusions: Taken together, these results demonstrate for the first time that the inhibitory effect of zinc during osteoclastogesis is caused by suppressing the Ca2+-Calcineurin-NFATc1 signaling pathway. Thus, zinc may be a useful therapeutic candidate for the prevention of bone loss caused by NFATc1 activation in osteoclasts.
- Open Access
- 15 August 2013
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 123 (9) , 4010-4022
Schnurri-3 regulates ERK downstream of WNT signaling in osteoblasts
Mice deficient in Schnurri-3 (SHN3; also known as HIVEP3) display increased bone formation, but harnessing this observation for therapeutic benefit requires an improved understanding of how SHN3 functions in osteoblasts. Here we identified SHN3 as a dampener of ERK activity that functions in part downstream of WNT signaling in osteoblasts. A D-domain motif within SHN3 mediated the interaction with and inhibition of ERK activity and osteoblast differentiation, and knockin of a mutation in Shn3 that abolishes this interaction resulted in aberrant ERK activation and consequent osteoblast hyperactivity in vivo. Additionally, in vivo genetic interaction studies demonstrated that crossing to Lrp5–/– mice partially rescued the osteosclerotic phenotype of Shn3–/– mice; mechanistically, this corresponded to the ability of SHN3 to inhibit ERK-mediated suppression of GSK3β. Inducible knockdown of Shn3 in adult mice resulted in a high–bone mass phenotype, providing evidence that transient blockade of these pathways in adults holds promise as a therapy for osteoporosis.
- 15 August 2013
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 123 (9) , 4010-4022
Open AccessSchnurri-3 regulates ERK downstream of WNT signaling in osteoblasts
Mice deficient in Schnurri-3 (SHN3; also known as HIVEP3) display increased bone formation, but harnessing this observation for therapeutic benefit requires an improved understanding of how SHN3 functions in osteoblasts. Here we identified SHN3 as a dampener of ERK activity that functions in part downstream of WNT signaling in osteoblasts. A D-domain motif within SHN3 mediated the interaction with and inhibition of ERK activity and osteoblast differentiation, and knockin of a mutation in Shn3 that abolishes this interaction resulted in aberrant ERK activation and consequent osteoblast hyperactivity in vivo. Additionally, in vivo genetic interaction studies demonstrated that crossing to Lrp5–/– mice partially rescued the osteosclerotic phenotype of Shn3–/– mice; mechanistically, this corresponded to the ability of SHN3 to inhibit ERK-mediated suppression of GSK3β. Inducible knockdown of Shn3 in adult mice resulted in a high–bone mass phenotype, providing evidence that transient blockade of these pathways in adults holds promise as a therapy for osteoporosis.
- Open Access
- 1 January 2013
- Published by The Korean Association of Immunobiologists in Immune Network
- Vol. 13 (4) , 111-115
Osteoimmunology: A Brief Introduction
Greenblatt MB, et al. Immune Netw. 2013 Aug;13(4):111-115. https://doi.org/10.4110/in.2013.13.4.111
- 1 January 2013
- Published by The Korean Association of Immunobiologists in Immune Network
- Vol. 13 (4) , 111-115
Open AccessOsteoimmunology: A Brief Introduction
Greenblatt MB, et al. Immune Netw. 2013 Aug;13(4):111-115. https://doi.org/10.4110/in.2013.13.4.111